IIVS | Inflammatory Cytokine Expression
604
page-template-default,page,page-id-604,page-child,parent-pageid-521,ajax_fade,page_not_loaded,,qode_grid_1300,footer_responsive_adv,hide_top_bar_on_mobile_header,qode-content-sidebar-responsive,qode-child-theme-ver-,qode-theme-ver-11.0,qode-theme-bridge,wpb-js-composer js-comp-ver-4.11.2.1,vc_responsive

Inflammatory Cytokine Expression

Product Safety Assessment Using an In Vitro Test System Based on Viability of and Cytokine Released by Reconstructed Human Epidermis (RhE) Models

  • Assay used for the evaluation of the skin irritation potential of topically administered test materials
  • Frequently used to address the irritation profile of (but not limited to) surfactant-based formulations with rinse-off applications
  • The assay allows ranking of test materials with anticipated low irritation potential using pro-inflammatory cytokine analyses such as interleukin IL-1α

Assay Endpoints

  • Tissue viability
  • Cytokine expression

Applicability Domain

  • Ingredients of finished products formulated to have low irritation potential
  • Undiluted (leave-on intended use) or diluted (rinse-off intended use) materials

Use

  • Ranking of test materials’ irritation potential
  • Qualification of benchmark materials
  • Correlation with clinical data